In conclusion, the present findings suggest that the CCL2/CCR2 axis plays an important role in glomerulonephritis in CKD and that the QC/isoQC inhibitor PQ529 suppresses this axis by inhibiting the modification of glutamine with a pyroglutamate residue at the CCL2 N-terminal, consequently suppressing the inflammation in the kidney and exerting inhibitory effects on the progression of chronic renal failure in glomerulonephritis rats. This evidence concerns the gene CCL2 and chronic kidney disease.